CLAIMS

1. A compound of the formula



1

or a pharmaceutically acceptable prodrug, salt or solvate thereof wherein:

each R^1 and R^{10} is independently H or OH;

R^2 is H or C_1-C_6 alkyl wherein the foregoing R^2 alkyl group is optionally substituted by 1 or 2 R^4 groups;

each R^3 is independently selected from C_6-C_{10} aryl or 5 to 10 membered heteroaromatic, and the heteroaromatic and aryl moieties of the foregoing R^3 groups are substituted by a $-CHR^9NR^{11}R^{12}$ group and optionally substituted by 1 to 4 R^4 groups;

each R^4 is independently selected from, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, halo, cyano, nitro, trifluoromethyl, difluoromethyl, trifluoromethoxy, azido, hydroxy, C_1-C_6 alkoxy, $-C(O)R^5$, $-C(O)OR^5$, $-NR^6C(O)OR^8$, $-OC(O)R^5$, $-NR^6SO_2R^8$, $-SO_2NR^5R^6$, $-NR^6C(O)R^5$, $-C(O)NR^5R^6$, $-NR^5R^6$, $-S(O)_j(CR^6R^7)_m(C_6$-C_{10} aryl), $-S(O)_j(C_1$-C_6 alkyl), $-(CR^6R^7)_m(C_6$-C_{10} aryl), $-O(CR^6R^7)_m(C_6$-C_{10} aryl), $-NR^6(CR^6R^7)_m(C_6$-C_{10} aryl), $-(CR^6R^7)_m$(4 to 10 membered heterocyclic), $-C(O)(CR^6R^7)_m(C_6$-C_{10} aryl), and $-C(O)(CR^6R^7)_m$(4 to 10 membered heterocyclic), wherein m is an integer from 0 to 4; j is an integer from 0 to 2, and said alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^4 groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-NR^6SO_2R^8$, $-SO_2NR^5R^6$, $-C(O)R^5$, $-C(O)OR^5$, $-OC(O)R^5$, $-NR^6C(O)OR^8$, $-NR^6C(O)R^5$, $-C(O)NR^5R^6$, $-NR^5R^6$, $-OR^5$, C_1-C_{10} alkyl, $-(CR^6R^7)_m(C_6$-C_{10} aryl), and $-(CR^6R^7)_m$(4 to 10 membered heterocyclic), wherein m is an integer from 0 to 4;

each R^5, R^9, R^{11}, R^{12}, R^{13} and R^{14} is independently selected from H, C_1-C_{10} alkyl, $-(CR^6R^7)_m(C_6$-C_{10} aryl), $-(CR^6R^7)_m(C_3$-C_{10} cycloalkyl), indanyl and $-(CR^6R^7)_m$(4 to 10 membered heterocyclic), wherein m is an integer from 0 to 4, and the foregoing R^5 , R^{11}, R^9 and R^{12}

substituents, except H, are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, benzyl, trifluoromethyl, trifluoromethoxy, azido, $-CH_2(C_2-C_6$ alkenyl), $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-NR^6R^7$, hydroxy, C_1-C_6 alkyl, and C_1-C_6 alkoxy;

or R^{11} and R^{12} can be taken together to form a 4 to 7 membered heterocyclic group optionally substituted by one R^{14} group;

each R^6 and R^7 is independently selected from H, $-C(O)(C_1-C_6$ alkyl), C_1-C_6 alkyl or $-(CH_2)_n(C_6-C_{10}$ aryl) wherein n is an integer from 0 to 2, and the foregoing aryl substituents are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, and azido;

$-NR^6R^7$ can be taken together to form the following structure



;

each R^8 is selected from the substituents provided in the definition of R^5 except R^8 is not H.

2. A compound acccording to claim 1 include those wherein R^3 is phenyl substituted by one $-CH_2NR^{11}R^{12}$ group and optionally substituted by 1 to 4 R^4 groups.

3. A compound according to claim 2 wherein said R^{11} and R^{12} groups are independently selected from C_1-C_{10} alkyl, $-(CR^6R^7)_m(C_6-C_{10}$ aryl), $-(CR^6R^7)_m(C_3-C_{10}$ cycloalkyl), indanyl and $-(CR^6R^7)_m$(4 to 10 membered heterocyclic), wherein m is an integer from 0 to 4, and the foregoing, R^{11} and R^{12} substituents, are optionally substituted by 1 to 3 substituents independently selected from halo, benzyl, trifluoromethyl, trifluoromethoxy, $-NR^6R^7$.

4. A compound according to claim 1 wherein one of the R^4 groups is halo and ortho to the ether oxygen.

5. A compound according to claim 4 wherein said halo group is chlorine.

6. A compound according to claim 1 wherein said compound is selected from the group consisting of:

3-(4-{(2S,3S,4S,5R)-5-[3-{2-chloro-4-[(methyl-napthalen-1—ylmethyl-amino)-methyl]-phenoxy}-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(4-benzylaminomethyl-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(-{(2S,4S,5R)-5-[3-(4-{[Benzyl-(2-dimethylamino-ethyl)-amino]-methyl}-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-4-hydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-acrylamide

3-(4-{(2S,3S,4S,5R)-5-[3-(2,3-Dichloro-4-{[(3-dimethylamino-propyl)-ethyl-amino]-methyl}-phenoxy)-1-methyl-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-acrylamide

3-(4-{(2S,3S,4S,5R)-5-[3-(4-(3-chloro-benzyl)aminomethyl-2-chloro-phenoxy)-1-methyl-(1Z)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(4-ethylamino-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(3-piperidinyl-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(4-benzylaminomethyl-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-4-hydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-{2-chloro-4-[(benzyl-methyl-amino)-methyl]-phenoxy}-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-{2-chloro-4-[(ethyl-methyl-amino)-methyl]-phenoxy}-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-{2-chloro-4-morpholin-4ylmethyl-phenoxy}-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(4-(3-chloro-benzyl)aminomethyl-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

and the pharmaceutically acceptable salts, prodrugs and solvates of said compounds.

7. A pharmaceutical composition for the treatment of a bacterial infection, a protozoal infection, or a disorder related to a bacterial infection or a protozoal infection, in a

mammal, fish, or bird which comprises a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

8. A method of treating a bacterial infection, a protozoal infection, or a disorder related to a bacterial infection or a protozoal infection, in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound of claim 1.